Abstract
INTRODUCTION
The incidence rates of ulcerative colitis (UC) and Crohn's disease (CD) are rising in parallel with rapid urbanization [1] . Patients with inflammatory bowel disease (IBD) seem to be at risk for developing pan creatitis [2] . Pancreatitis in IBD has several causes: it can be an extraintestinal manifestation (EIM) [36] , or it can be druginduced [710] or autoimmunerelated [11] . Gallstones and alcohol abuse are also longestablished risk factors for acute pancreatitis [12] . The relationship between IBD and autoimmune pancreatitis (AIP) is mainly confined to UC [13, 14] . Several studies have reported positive associations between risk for acute pancreatitis and IBD severity [1517] . To our knowledge, however, no study has evaluated the clinical course of UC patients who develop pancreatitis according to its etiology. Recently, we described the clinical course of UC in a cohort of 2802 Korean patients, and reported a cumulative colectomy rate of 14.2% during a follow up period of 20 years [18] . In this study, we aimed to describe the clinical course of UC patients who develop acute pancreatitis in a large prospective cohort, and to compare these patients with the rest of the UC cohort. In particular, AIP and druginduced pancreatitis were analyzed, and the clinical outcomes were compared according to the etiology.
MATERIALS AND METHODS

Patients
This study enrolled patients with UC who were managed at Asan Medical Center, a tertiary university hospital in Seoul, South Korea, between June 1989 and May 2015. All patients were diagnosed with UC between 1977 and 2015, based on composite criteria of cli nical, radiological, endoscopic, and histopathological findings [19, 20] .
Diagnosis of acute pancreatitis
AIP was diagnosed using the International Consensus Diagnostic Criteria [21] . Druginduced pancreatitis was clinically diagnosed after excluding other potential causes of pancreatitis. In druginduced pancreatitis cases where causal relationship was uncertain, patients were rechallenged. Severity of acute pancreatitis was classified using the revised Atlanta classification [22] .
Study design
The IBD registry of Asan Medical Center is a well established prospectively maintained registry, and has been described previously [18, 2325] . We used the clinical data from this prospectively maintained registry to retrospectively analyze the incidence of acute pancreatitis among patients with UC and the clinical course of UC patients who developed acute pancreatitis. The information obtained from the registry included sex, date of birth, date of symptom onset, date of UC diagnosis, family history of IBD, smoking status, disease activity, disease extent at diagnosis and during the course, medication use, and colectomy. The extent of disease was determined on the basis of endoscopic findings. Proctitis was defined as disease < 15 cm from the anal verge, leftsided colitis as disease up to the splenic flexure, and extensive colitis as disease beyond the splenic flexure [20] . To investigate the subsequent evolution of the disease, we evaluated the rates of proximal disease extension and of colectomy.
Treatment policy
Our treatment strategies for UC were detailed previously [18, 26] and are based on a stepup approach that is similar to that of Western countries. To briefly summarize, topical and/or oral 5aminosalicylates were used to induce and maintain remission in mild to moderate UC; systemic corticosteroid therapy was used for moderately to severely active disease; and thiopurines (azathioprine or 6mercaptopurine) and, in case of failure, antitumour necrosis factor (TNF) agents were used for steroiddependent or steroid refractory patients. Pancreatitis was managed conservatively with fasting and antibiotics after discontinuation of the causative drug if present. Patients with AIP were treated with corticosteroids (prednisone 0.6 mg/kg to 1 mg/kg) for 2 to 4 wk, with a taper of 5 mg/d every week. After induction treatment with corticosteroids, immunomodulator agents were given, unless contraindicated.
Statistical analysis
Continuous variables are presented as either mean with SD or median with range. Fisher's exact test was used to compare proportions, and the MannWhitney U test was used to compare quantitative variables.
Logistic regression with a forward variable selection was used to calculate the adjusted OR and 95%CI for colectomy. In multivariable analysis, the variables with P < 0.05 on bivariate analysis were entered into the model. For druginduced pancreatitis, clinical characteristics and disease course were compared with nonpancreatitis patients who had also been treated with the same drugs. Stata ver. 14.2 (StataCorp, College Station, TX, United States) was used for statistical analyses. 
Ethical considerations
RESULTS
Patient population
A total of 3307 UC patients [1812 males (54.8%), 
Incidence of acute pancreatitis
Among the 3307 study subjects, 51 (1.5%) developed acute pancreatitis. Among the acute pancreatitis patients, 23 (45.1%) had druginduced (13 thiopurine induced and 10 aminosalicylateinduced), 13 (25.5%) had autoimmune, 9 (17.6%) had idiopathic, and 6 (11.8%) had gallstoneinduced pancreatitis.
AIP developed in 0.40% of 3307 UC patients. All cases of AIP were type 2 (four definitive, nine induced pancreatitis occurred after taking oral forms. Thiopurineinduced pancreatitis developed in 1.75% of 742 UC patients who were treated with thiopurines. The median interval from the commencement of thiopurines to the development of pancreatitis was 18 (range, 0131) d.
There was one patient with AIP whose severity was classified as moderate; all other patients had mild acute pancreatitis.
Demographics and clinical characteristics of UC patients with pancreatitis
Baseline demographic and clinical characteristics of UC patients with and without pancreatitis are shown in Tables 1 and 3 . Median age at diagnosis of UC was significantly younger among AIP patients compared to those without pancreatitis. Patients with autoimmune and aminosalicylateinduced pancreatitis had more extensive UC compared to those without pancreatitis.
Clinical course
All 13 patients with AIP showed a good response to corticosteroids, and there were no cases of recurrence during the median followup of 27.8 mo (range, 3.281.9) following diagnosis of AIP. All 23 patients with druginduced pancreatitis recovered uneventfully after cessation of the causative agent and with conservative care. Six of ten patients with aminosalicylateinduced pancreatitis underwent aminosalicylate rechallenge, and all cases developed repeat episodes. After per manent cessation of aminosalicylate, all 10 patients showed no further recurrence of pancreatitis during the median followup of 91.6 (range, 10.7174.8) mo. One of 13 patients with thiopurineinduced pancreatitis underwent thiopurine rechallenge and showed a positive response. There was no recurrence of acute pancreatitis during the median followup of 21.0 (range, 0.389) mo.
Among 13 patients with AIP, medical therapy for probable, UC included aminosalicylates in two, thiopurines in nine, and antiTNF agents in three. Among 10 patients with aminosalicylateinduced pancreatitis, medical therapy for UC included thiopurines in eight, and anti TNF agents in four. Among 13 patients with thiopurine induced pancreatitis, medical therapy for UC included aminosalicylates in three and antiTNF agents in ten.
Among antiTNF agentnaive patients, subsequent use of antiTNF agents was observed in 9.1% (1/11) of autoimmune, 40% (4/10) of aminosalicylate induced, and 75% (9/12) of thiopurineinduced pancreatitis cases. Among nonpancreatitis patients, antiTNF agents were used in 8.26% (269/3256). The rate of antiTNF agent use was significantly higher among aminosalicylateinduced and thiopurine induced pancreatitis patients, after adjusting for baseline disease extent [adjusted OR (95%CI), 5.16 (1.4218.67) and 6.90 (1.8325.98), respectively] ( Table 4) .
Colectomy rates for autoimmune, aminosalicylate induced, and thiopurineinduced pancreatitis patients, as well as for nonpancreatitis patients, were 15.4% (2/13), 20% (2/10), 15.4% (2/13), and 7.3% (239/3256), respectively. Compared to those without pancreatitis, patients with pancreatitis did not show a significant increase in colectomy rates during follow up, after adjusting for baseline disease extent (Table 5 ).
DISCUSSION
In this study, we analyzed the frequency and clinical course of acute pancreatitis among UC patients in a large, wellestablished prospective cohort. To the best of our knowledge, this is the largest single study to date to describe the frequency and clinical course of AIP.
The most common causes of acute pancreatitis in IBD patients are reported to be gallstones and drugs [27] . Thiopurines are the drugs most frequently implicated as a cause of acute pancreatitis in IBD patients, with a reported incidence of 3%4% [28, 29] . In a prospective study among IBD patients, azathioprine induced acute pancreatitis occurred in 37 of 510 patients (7.3%) [30] . In our study, a higher rate of acute pancreatitis was observed in thiopurine treated patients (1.75%), compared with the rates of autoimmune (0.40%) and aminosalicylateinduced cases (0.30%). UC patients are reported to be at an increased risk of developing acute pancreatitis compared to the general population [31] . According to a study performed in 2003, the annual incidence of acute pancreatitis in South Korea was 19.4 per 100000 persons [32] . In our patients, the annual incidence of acute pancreatitis was 152.9 (95%CI: 113.4206.1) per 100000 persons (data not shown). The incidence was higher among our patients, and further analysis using data from the general population is required to draw firm conclusions.
Ueki et al [11] reported that five (0.5%) of 961
Japanese patients with UC developed AIP during a mean followup period of 86 mo. This figure is comparable with the 0.4% in our study. Although AIP is uncommon among IBD patients, it is interesting to note that the reported prevalence of IBD in patients with AIP is 6% to 27%, predominantly UC [27, 3335] .
AIP is subclassified into two separate entities: type 1 AIP, or lymphoplasmacytic sclerosing pancreatitis (LPSP), and type 2 AIP, or idiopathic duct centric pancreatitis (IDCP) [21, 36] . Type 2 AIP is most commonly associated with IBD, with a reported frequency of 16% to 30% [37, 38] . All of our patients with AIP had type 2 AIP. It is interesting that two cases of AIP occurred before the diagnosis of UC. There have been several reports of AIP occurring before the diagnosis of CD [31, 32, 39, 40] , but to the best of our knowledge, there have been no reports of AIP that preceded UC. Our results suggest that patients with repeated episodes of unexplained acute pancreatitis should be evaluated for inflammatory bowel disease.
Among the druginduced pancreatitis patients, some cases were diagnosed only after a prolonged period since starting the drug. It is possible that objective diagnosis of pancreatitis was delayed, since symptoms of pancreatitis and UC, such as abdominal pain, can overlap. It is also possible that the patient could have skipped the drug after experiencing the side effect, without notifying the attending physician. In previous studies, the median duration of azathioprine therapy before diagnosis of pancreatitis was 26 (range, 6720) d [41] and 25 (range, 530) d [29] , which was similar to that in our study [median, 18 d (range, 0131)]. A case of pancreatitis after 18 mo of mesalamine treatment has also been reported [42] . Patients with AIP were younger and had more extensive disease than those without acute pancreatitis. Most patients with aminosalicylateinduced pancreatitis had extensive disease, but the reason is not clear. There were significantly more females among thiopurine induced pancreatitis patients compared to non pancreatitis patients in our study (69.2% vs 38.3%; P = 0.040). In a prospective study of 37 patients with azathioprineinduced acute pancreatitis, 24 (64.9%) were female (P = 0.06) [30] . A study on CD patients [29] reported that females over 40 years of age had an increased risk for developing thiopurinerelated adverse events, but the reasons for increased thiopurine induced pancreatitis among females is not clear. The incidence of thiopurineinduced pancreatitis is reported to be 3%4% among IBD patients [2729] . Among our patients, thiopurineinduced pancreatitis developed less frequently (1.75% of thiopurine users). The reason for this is not clear, but it might represent a distinct characteristic of our cohort.
In our study, there was no case of relapse of pan creatitis among AIP patients, once treated. All our AIP patients had type 2 AIP, and previous studies reported that relapse of pancreatitis is rare in type 2 AIP compared to type 1 AIP [43, 44] . In a large multicenter study involving 978 subjects with type 1 AIP and 86 with type 2 AIP, the relapse rate was 31% with type 1 and 9% with type 2 (P < 0.001) [44] . Considering the usual stepup approach for treating UC, the higher rate of antiTNF agent use among thiopurineinduced pancreatitis cases is expected. Aminosalicylateinduced pancreatitis patients also showed a higher rate of antiTNF agent use, presumably because a high proportion had extensive disease (90%). Although the rate of antiTNF use was high, the colectomy rates were not significantly different in acute pancreatitis patients compared to nonpancreatitis patients. The colectomy rate in our cohort was 7.3%, which is comparable to those of previous studies [4549] . AIP is a new diagnostic entity, only established in 2011 [21] . In addition, the tendency among Korean physicians to prescribe thiopurine only showed a rising trend in recent years [18] . For these reasons, durations of followup for autoimmune and thiopurineinduced pancreatitis patients were shorter than those for non pancreatitis patients. Therefore, directly comparing the colectomy rate with nonpancreatitis patients might have led to falsenegative results. As physicians are becoming more aware of AIP, and as thiopurines are being used more frequently [18] , future studies using longer analysis times seem to be required. This study has several limitations. First, since this study was conducted at a single tertiary referral center, the conclusions could have been biased. Second, we could not analyze the severity of pancreatitis in detail, due to limitations in clinically available data. Third, as mentioned above, the followup time of autoimmune and thiopurineinduced pancreatitis patients was relatively short, which could have led to false negative results regarding subsequent colectomy rates. Fourth, the followup interval was variable among patients, which could have led to the apparently low rate of thiopurineinduced pancreatitis.
In conclusion, we described the frequency and clinical course in UC patients who developed acute pancreatitis in a large, prospectively maintained cohort. Compared with nonpancreatitis UC cases, the baseline disease extent in patients with autoimmune and aminosalicylateinduced pancreatitis was greater, and age at diagnosis of UC with AIP was younger. Anti TNF agents were used more frequently in UC patients who had developed aminosalicylate or thiopurine induced pancreatitis. Despite these differences, the clinical course of UC patients who developed acute pancreatitis was not significantly different. Further studies with longer followup are required.
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Background
Patients with ulcerative colitis (UC) seem to be at risk for developing acute pancreatitis, which can be an extraintestinal manifestation of the UC, druginduced, or autoimmune-related. The clinical course of UC in patients who develop acute pancreatitis is not well known.
Research frontiers
Acute pancreatitis can cause a significant impact on the course of UC by requiring change in treatment or by acting as a prognostic factor itself. This study investigated the clinical course of UC in patients who developed acute pancreatitis in a large, well-established, prospectively maintained cohort. Particular focus was given to the clinical course of patients who developed autoimmune, aminosalicylate-induced and thiopurine-induced pancreatitis.
Innovations and breakthroughs
The results showed that UC patients who developed acute pancreatitis had a non-significantly higher colectomy rate compared with those without pancreatitis, after adjusting for disease extent of UC at baseline. The acute pancreatitis in most patients was mild. All patients with autoimmune pancreatitis (AIP) had type 2 and there was no recurrence of the pancreatitis.
Applications
The data in this article can be used to predict the clinical course of patients with UC who develop acute pancreatitis, which seems to be mild in most cases. There was no recurrence of AIP. Patients with aminosalicylate-induced and thiopurine-induced pancreatitis had higher rates of treatment with a biologic.
Terminology
AIP is a peculiar type of pancreatitis of presumed autoimmune etiology, subclassified as type 1, lymphoplasmacytic sclerosing pancreatitis, and type 2, idiopathic duct centric pancreatitis.
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